In line with studies on ALK-positive lung cancers, which have showed the variable clinical outcome of patients with different EML4-ALK fusion variants26,27, we also observed prolonged PFS outcome in patients harboring the v1 variant compared with those carrying the v3 variant. The gene discussed is ALK; the disease is lung cancer.